Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into an R&D agreement with PerkinElmer Health Sciences to design an assay for evaluating a patient's risk of developing hepatocellular carcinoma.

The assay will be based on Trovagene's TrNA technology, the company said in a document filed with the US Securities and Exchange Commission, adding that both firms will jointly validate the assay and evaluate the possibility of combining the TrNA technology with PerkinElmer's technology for automation of nucleic acid isolation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.